Optimizing Oncology Express Scripts Integration for Oral Oncolytics

Klivira provides robust oncology Express Scripts integration, specifically designed to automate and accelerate prior authorization for high-cost oral oncolytics under the pharmacy benefit.

Managing prior authorizations in oncology presents unique challenges due to the complexity of regimens, frequent treatment changes, and the dual medical/pharmacy benefit split. For oral oncolytics, Express Scripts, as a major Pharmacy Benefit Manager (PBM), is a critical touchpoint. Efficient integration is essential to mitigate delays in treatment initiation and ensure timely access for cancer patients.

The Challenge of Oncology Pharmacy Benefit PAs

Oncology care often involves high-cost oral targeted therapies and chemotherapies, which fall under the pharmacy benefit and require prior authorization through PBMs like Express Scripts. Unlike IV infusions, these medications are dispensed by pharmacies, necessitating a different PA workflow. The rapid evolution of oncology guidelines, coupled with payer-specific requirements, complicates the process, often leading to manual submissions, delays, and administrative burden on oncology teams.

Key PA Triggers for Oral Oncolytics via Express Scripts

Initiation of new oral targeted therapies or oral chemotherapy regimens.
Changes in existing oral oncolytic regimens due to progression or toxicity.
Requests for high-cost supportive care medications falling under the pharmacy benefit.
Documentation of specific molecular markers (e.g., EGFR, ALK, PD-L1, BRCA) to justify targeted therapy.
Adherence to NCCN Clinical Practice Guidelines and Compendium for on-label and off-label use.

Klivira's Approach to Oncology Express Scripts Integration

Klivira's platform provides a direct, intelligent integration with Express Scripts for pharmacy benefit prior authorizations. This capability ensures that requests for oral oncolytics are routed correctly and populated with the necessary clinical documentation directly from the EMR. Our system's NCCN-compendium-aware logic helps ensure submissions meet payer criteria, minimizing common denial reasons such as 'off-label use without compendium support' or 'documentation gaps'.

Streamlining Documentation for Express Scripts Oncology PAs

Automated extraction of diagnosis confirmation, including pathology reports and AJCC TNM staging.
Capture of molecular marker results relevant to the requested oral oncolytic.
Documentation of prior-line treatment response and rationale for regimen changes.
Integration of ECOG or Karnofsky performance status scores.
Automated inclusion of NCCN Compendium citations for off-label indications where accepted by Express Scripts.

Addressing the Medical vs. Pharmacy Benefit Split

Oncology patients frequently receive both medical benefit (IV infusions, radiation) and pharmacy benefit (oral oncolytics) treatments concurrently. Klivira intelligently identifies the benefit category for each drug, routing medical benefit PAs through appropriate medical channels (e.g., X12 278) and pharmacy benefit PAs through PBM channels like Express Scripts. This dual-channel capability ensures comprehensive PA coverage across the patient's entire treatment plan, preventing delays caused by misrouted requests.

Benefits for Oncology Revenue Cycle and PA Teams

By automating the oncology Express Scripts integration, Klivira significantly reduces the manual effort and administrative burden associated with pharmacy benefit prior authorizations. This leads to faster PA approvals, fewer denials, and improved treatment initiation times, directly impacting revenue cycle efficiency and, critically, patient outcomes. Our platform's ability to track concurrent PA events across a patient's treatment course provides complete visibility and control over the complex oncology PA landscape.

Frequently asked questions

What types of oncology drugs typically require Express Scripts prior authorization?

Express Scripts, as a PBM, primarily handles prior authorizations for oral oncolytics, oral targeted therapies, and certain high-cost supportive care medications that fall under the pharmacy benefit. These are drugs dispensed by retail or specialty pharmacies, not administered in a clinic setting.

How does Klivira handle the distinction between medical and pharmacy benefit oncology drugs?

Klivira's platform is designed to identify whether an oncology drug falls under the medical or pharmacy benefit. It then intelligently routes the prior authorization request to the appropriate channel — either via X12 278 or payer portals for medical benefit drugs, or through PBM integrations like Express Scripts for pharmacy benefit drugs.

What clinical documentation does Klivira automate for Express Scripts oncology PAs?

Klivira automates the extraction and submission of critical documentation, including diagnosis confirmation (pathology, staging), molecular marker results, prior treatment history and response, performance status (ECOG/Karnofsky), and NCCN Compendium citations, ensuring comprehensive submissions to Express Scripts.

Can Klivira integrate with Express Scripts for both new prior authorizations and renewals?

Yes, Klivira's integration capabilities support both initial prior authorization submissions and subsequent renewals or modifications for oral oncolytics managed by Express Scripts. The system tracks the PA status and proactively alerts teams for upcoming renewals, minimizing treatment interruptions.

How does Klivira's Express Scripts integration help reduce oncology PA denials?

By ensuring accurate, complete, and guideline-compliant submissions from the outset, Klivira significantly reduces common denial reasons such as 'documentation gaps' or 'off-label use without compendium support.' The system's NCCN-aware logic helps align requests with payer medical policy criteria.